A new MRI technique, Vessel Architectural Imaging, can identify patients with aggressive brain cancer who are most likely to benefit from treatment. The technique allows for personalized medicine and quicker initiation of alternative treatments.
A new MR analysis technique called vessel architectural imaging (VAI) can identify changes in brain tumor blood vessels within days of anti-angiogenesis therapy initiation. VAI has shown that 10 out of 30 patients with recurrent glioblastoma responded to the treatment, surviving six months longer than non-responders.
A randomized phase II trial is investigating a personalized vaccine made from a patient's own brain tumor, combined with Avastin, for treating recurrent glioblastoma multiforme. The trial aims to extend survival and slow tumor progression, offering new hope for patients with limited treatment options.
Researchers develop bioengineered peptide to distinguish tumors from healthy tissue, demonstrating promising results in imaging medulloblastomas in lab mice. The new approach offers real-time imaging and potential for targeted drug delivery to cranial tumors.
Researchers found that IL-17 signaling in tumor-infiltrating T cells encourages resistance to VEGF-blockade in mouse models. Inhibiting IL-17 with monoclonal antibodies may improve clinical efficacy of VEGF-targeting drugs, a potential new strategy for cancer therapy.
Dr. Lu Zhou has been awarded the Children's Tumor Foundation Young Investigator Award to develop therapies based on existing drugs for NF tumours, aiming to improve quality of life and survival rates for children with this condition.
Researchers developed digital PCR technology to detect IDH1 mutation in CSF of patients with brain tumors, improving treatment choice and patient care. The technique has potential for noninvasive biomarker identification and personalized medicine.
A laboratory study shows that a nanotechnology drug called SapC-DOPS crosses the blood-brain barrier and targets brain-tumor cells, retarding growth of tumor blood vessels. The agent also sensitizes hypoxic cells to killing, supporting further development as a novel treatment for glioblastoma.
Researchers at Yale University found that a human metastatic tumor can arise when a leukocyte and a cancer cell fuse to form a genetic hybrid, potentially explaining how cancer cells travel to distant organs. The study's findings provide the first evidence of such a phenomenon in humans and could lead to new therapy targets.
A cancer doctor turned to immunotherapy after his Great Dane's lung cancer diagnosis. The treatment, using an engineered vaccine, significantly prolonged the dog's life and has sparked interest in testing on human brain cancer patients.
Researchers found that brain tumor cells with intact IDH gene produce a key enzyme BCAT1, which boosts cell proliferation. Blocking BCAT1 reduced tumor aggressiveness and released neurotransmitter glutamate. The study suggests using BCAT1 as a therapeutic target for glioblastoma treatment.
Researchers have discovered how and why an anti-cancer therapy stops working when tumor cells become starved of oxygen. This new understanding could lead to the development of more effective therapies for cancer treatment.
A new molecular imaging technique, F-18 FET, has been shown to be highly effective in detecting and differentiating brain lesions in children, with an accuracy rate of 94%. This study improves the clinical management of pediatric brain cancer patients by providing more accurate information about tumor progression and treatment.
A clinical trial found that adding bevacizumab to standard treatment for glioblastoma did not improve overall survival or progression-free survival. However, patients in the bevacizumab arm experienced a greater decline in cognitive function and symptom burden compared to those on placebo.
Researchers at Lund University have developed a vaccine-based treatment that stimulates the immune system to fight brain tumors, with promising results in animal experiments. The treatment has shown significant effectiveness in curing rats of their brain tumors.
In a large, international randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. No significant difference in progression-free survival was observed between the two treatment strategies, with radiotherapy numerically favored. Molecular tumor characterization may allow personalized treatment approaches.
Researchers discovered that targeting CTLA-4 and OX-40 proteins on regulatory T cells can help eliminate cancer cells. Mice treated with antibodies against these proteins had smaller tumors and improved survival, including clearance of brain metastases.
A modified poliovirus is infecting and killing glioblastoma brain tumor cells with encouraging results in an ongoing phase 1 study, researchers report. The virus-based therapy, known as PVSRIPO, triggers the immune system to attack infected tumor cells.
Researchers developed a mouse model to study MPNST, identifying genes FOXR2 and NF1/PTEN pathways involved in its development. The study aims to repurpose existing therapeutics for MPNST treatment and explore new targeting strategies.
Researchers at Plymouth University Peninsula Schools of Medicine and Dentistry have discovered how the loss of a tumour suppressing protein leads to abnormal cell division in the brain and nervous system. The study's findings may lead to new drug-based therapies to reduce or negate the need for multiple surgeries or radiotherapies.
Researchers at the Salk Institute have identified TR4 as a protein that drives the formation of pituitary tumors in Cushing's disease, which could lead to a new therapeutic approach for this potentially life-threatening disorder. The study found that targeting this pathway could benefit treatment of CD.
Researchers at Lund University have discovered that exosome molecular profiles reflect the aggressiveness of brain tumours, offering a new approach for diagnosis and treatment. The study's findings suggest that exosomes could serve as biomarkers to guide patient care and monitor treatment response.
A gene sequencing project has identified mutations responsible for more than half of a subtype of childhood brain tumor that takes a high toll on patients. The study found that the tumors are susceptible to drugs already in development, offering new hope for treatment.
Researchers developed a quick and simple fMRI task to localize critical brain areas governing speech and other functions. The new protocol accurately localized the anterior and posterior language areas of the brain in about 90% of subjects, including patients undergoing surgery for epilepsy or tumors.
Researchers explore the potential of EVs as biomarkers, delivery vehicles, and immune modulatory tools for brain cancer diagnosis, monitoring, and treatment. Extracellular vesicles may provide a way for tumor cells to alter the microenvironment, enabling growth and spread while evading immune responses.
A new MRI-guided laser treatment has been found to be safe and effective in treating recurrent glioblastoma, a type of brain tumor. The procedure uses a minimally invasive approach to destroy tumors, with nine out of ten patients showing improved response and survival rates.
Researchers at Penn Medicine developed a personalized brain mapping technique using diffusion tensor imaging (DTI) to preserve language, visual, and motor functions during brain tumor surgeries. This technique improved accuracy and extended survival in some cases, with a median survival time of 21.2 months.
Researchers at Henry Ford Hospital have discovered a novel approach for treating malignant brain tumors using microvesicles generated from mesenchymal bone marrow cells. The treatment significantly reduced tumor volume in living lab rats, suggesting a potential new therapy for glioma, a common and aggressive type of brain cancer.
Researchers found that blocking substance P binding to its receptor NK1 with the anti-nausea drug Emend halted brain tumor growth and caused cell death in tumor cells. This breakthrough offers new opportunities for studying possible brain tumor treatments.
Researchers found a high prevalence of low T3 syndrome before and after surgery, associated with unfavorable clinical outcomes and depressive symptoms. Perioperative low T3 syndrome was linked to a five-fold increased risk of poor outcome.
Johns Hopkins researchers have discovered that mesenchymal stem cells derived from human adipose tissue can seek out and destroy glioblastoma cancer cells in the brain. This innovative approach may provide a new tool for accessing difficult-to-reach areas of the brain where cancer cells proliferate.
Researchers from Plymouth University have identified the role of Merlin in regulating axon integrity, a key factor in peripheral neuropathy. This discovery could lead to effective drug therapies for patients with neurofibromatosis type 2 (NF2) suffering from peripheral neuropathy.
Researchers identified placental growth factor (PlGF) as crucial for medulloblastoma growth and spread. Blocking this pathway led to regression of all four molecular subtypes in mouse models.
Researchers describe the use of 5-aminolevulinic acid (5-ALA) fluorescence to guide resection of recurrent glioblastoma multiforme, revealing a pathway of tumor spread through brain regions inaccessible to MRI. This technique increases the success of achieving maximum resection.
A new gene, SMARCE1, has been identified as responsible for causing spinal meningioma, an inherited form of tumor. The discovery was made using next-generation sequencing technology and could lead to better testing, treatment, and care for patients.
Researchers discover pairing Avastin with dasatinib can stop lethal spread of aggressive brain cancer glioblastoma multiforme. The combination reduces tumor growth and blocks further spread by inhibiting protein migration.
Researchers developed a diffusion abnormality index (DAI) to measure brain tumor response to radiation therapy. The study showed that changes in DAI can predict post-treatment response with high sensitivity and specificity.
A study published in Neurosurgery found that subcortical damage during awake craniotomy for brain tumor surgery can lead to worsening neurological deficits. The researchers analyzed data from 241 patients and found that 36 developed new neurological abnormalities while the surgeon was operating in the subcortex.
Researchers identified a compound called TIC10 that stimulates the tumor suppression capabilities of TRAIL, inducing cancer cell death in mice. The compound is effective in cancer cell samples and cell lines resistant to conventional therapies, showing promise as a new treatment option for advanced cancer.
A team of researchers at Yale University has identified four new genetic suspects linked to the origins and treatment of meningiomas. The study found that tumors mutated with these genes tend to be located in different areas of the brain, indicating their likelihood of becoming malignant.
Researchers developed a new method to predict individual patient's brain tumor growth, enabling physicians to rapidly identify effective therapies. The approach accounts for tumor features such as shape, density, and growth rate, allowing clinicians to distinguish between patients with different tumor characteristics.
The new book, Navigating Life with a Brain Tumor, offers comprehensive guidance on managing brain tumors, including treatment options, side effects, and coping strategies. Written by neuro-oncologists from Mayo Clinic and Tufts Medical Center, the book aims to empower patients to be active participants in their care.
A research team at Plymouth University has identified a new group of growth factor receptors that signal to brain tumors, which are over-expressed and activated in certain tumors. The study shows that by interfering with the activation, tumor cells can be corrected, paving the way for non-surgical therapies.
A study published in The Lancet found that approximately one of every five individuals with kidney tumors common in patients with tuberous sclerosis complex has had a kidney removed unnecessarily due to misdiagnosis. Everolimus successfully shrinks these tumors, offering an alternative to surgery.
Researchers from Wake Forest Baptist Medical Center found that smaller radiation fields can be safely used to treat glioblastoma patients without compromising treatment efficacy. This study suggests that focusing radiation on smaller areas of the brain may help preserve cognition and reduce symptoms associated with radiation toxicity.
Researchers found ID proteins essential for retaining glioma-initiating cells in a specific extracellular niche, maintaining their cancer-promoting properties. The study's results suggest ID proteins as potential therapeutic targets for glioma treatment.
Researchers at Duke Medicine have developed an artificial protein that stimulates the body's natural immune system to fight cancer. In a study published in the Proceedings of the National Academy of Sciences, the therapy was shown to cure brain tumors in six out of eight mice, with no harm to surrounding normal tissue.
Pitt Cancer Institute researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line that could offer new hope for drug treatment to destroy cancer cells. The findings may lead to the development of adjuvant chemotherapy drugs that will improve patient survival rates.
Researchers identified a previously unidentified virus in raccoons that may be contributing to the development of brain tumors. The study found that this virus, dubbed raccoon polyomavirus, is present in all affected animals and may play a role in tumor formation.
Researchers at Barrow Neurological Institute found that a ketogenic diet significantly enhances the anti-tumor effect of radiation, leading to improved survival rates for mice with malignant gliomas. The study suggests that the diet could be used as an adjuvant therapy without FDA approval.
Researchers used PET imaging to evaluate tumor grade and cellular proliferation in patients with gliomas. The study found that F-18-FLT PET provided a more comprehensive view of tumor grade and correlated with overall survival, making it a valuable tool for guiding treatment.
A new study found a four-fold increase in breast cancer incidence among women with neurofibromatosis-1, prompting recommendations for earlier screening. The researchers suggest annual manual breast exams and mammograms beginning at age 40 for this high-risk population.
Researchers found that natural killer cells in patients quickly eliminate anticancer viruses used to treat brain tumors, reducing their effectiveness. Blocking these immune cells may help improve treatment outcomes for glioblastoma patients.
Pituitary centers of excellence could provide optimal clinical management for patients with pituitary tumors, highlighting the importance of multidisciplinary collaborative environments. The proposal suggests three key missions: comprehensive patient care, residency training, and research contributions.
A new Johns Hopkins research suggests that uninsured brain cancer patients are twice as likely to die in the hospital after undergoing surgery to remove a tumor. Despite this, patients with government-subsidized insurance through Medicaid had survival rates closer to those with private insurance.
A study published in Archives of Surgery found that uninsured patients with brain tumors had higher in-hospital mortality rates than privately insured patients. The disparity was pronounced in teaching hospitals, highlighting the need for further research into insurance-related disparities in medical outcomes.
Sanford-Burnham researchers found that different brain tumor cell types respond to distinct treatments due to varying growth factor regulation. This discovery offers potential for more effective and less harmful treatments tailored to individual tumors.
A recent Johns Hopkins study found that repeated surgeries to remove glioblastomas, the most aggressive brain tumors, can increase median survival time from 14 months to 26.6 months. This may be due to increased efficacy of radiation and chemotherapy with each successive surgery.
A phase 2 study reports that the combination of lapatinib and capecitabine reduces brain tumour size by at least 50% in two-thirds of women with advanced HER2-positive breast cancer. This treatment delays radiotherapy, which can impair cognitive function, offering a potential advance for patients.
Researchers at the Salk Institute have discovered that glioblastoma multiforme (GBM) can originate from cortical neurons, challenging previous assumptions about its origins. This finding suggests potential new targets to treat these deadly brain tumors and may help slow progression and recurrence.